19. Xu F, Wei Y, Tang Z, Liu B, Dong J. Tumor−associated macrophages in lung
cancer: friend or foe? (Review). Mol Med Rep (2020) 22(5):4107–15. doi: 10.3892/
mmr.2020.11518
20. Starr T, Bauler TJ, Malik-Kale P, Steele-Mortimer O. The phorbol 12-myristate13-acetate differentiation protocol is critical to the interaction of THP-1 macrophages
with salmonella typhimurium. PloS One (2018) 13(3):e0193601. doi: 10.1371/
journal.pone.0193601
1. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al.
Pembrolizumab versus chemotherapy for PD-L1-Positive non-Small-Cell lung cancer.
N Engl J Med (2016) 375(19):1823–33. doi: 10.1056/NEJMoa1606774
2. Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, et al. Fiveyear follow-up of nivolumab in previously treated advanced non-Small-Cell lung
cancer: results from the CA209-003 study. J Clin Oncol (2018) 36(17):1675–84. doi:
10.1200/JCO.2017.77.0412
21. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion.
Nat Rev Immunol (2015) 15(8):486–99. doi: 10.1038/nri3862
3. Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al.
Pembrolizumab plus chemotherapy in metastatic non-Small-Cell lung cancer. N Engl J
Med (2018) 378(22):2078–92. doi: 10.1056/NEJMoa1801005
22. Stutvoet TS, Kol A, de Vries EG, de Bruyn M, Fehrmann RS, Terwisscha van
Scheltinga AG, et al. MAPK pathway activity plays a key role in PD-L1 expression of
lung adenocarcinoma cells. J Pathol (2019) 249(1):52–64. doi: 10.1002/path.5280
4. Chamoto K, Hatae R, Honjo T. Current issues and perspectives in PD-1 blockade
cancer immunotherapy. Int J Clin Oncol (2020) 25(5):790–800. doi: 10.1007/s10147019-01588-7
23. Ivashkiv LB. IFNg: signalling, epigenetics and roles in immunity, metabolism,
disease and cancer immunotherapy. Nat Rev Immunol (2018) 18(9):545–58.
doi: 10.1038/s41577-018-0029-z
5. Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1
checkpoint. Immunity (2018) 48(3):434–52. doi: 10.1016/j.immuni.2018.03.014
24. Hill W, Lim EL, Weeden CE, Lee C, Augustine M, Chen K, et al. Lung
adenocarcinoma promotion by air pollutants. Nature (2023) 616(7955):159–67.
doi: 10.1038/s41586-023-05874-3
6. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumorassociated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune
evasion. Nat Med (2002) 8(8):793–800. doi: 10.1038/nm730
25. Mantovani A, Dinarello CA, Molgora M, Garlanda C. Interleukin-1 and related
cytokines in the regulation of inflammation and immunity. Immunity (2019) 50
(4):778–95. doi: 10.1016/j.immuni.2019.03.012
7. Genova C, Dellepiane C, Carrega P, Sommariva S, Ferlazzo G, Pronzato P, et al.
Therapeutic implications of tumor microenvironment in lung cancer: focus on immune
checkpoint blockade. Front Immunol (2021) 12:799455. doi: 10.3389/
fimmu.2021.799455
26. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the
future. Immunity (2013) 39(6):1003–18. doi: 10.1016/j.immuni.2013.11.010
8. Sumimoto H, Takano A, Teramoto K, Daigo Y. RAS-Mitogen-Activated protein
kinase signal is required for enhanced PD-L1 expression in human lung cancers. PloS
One (2016) 11(11):e0166626. doi: 10.1371/journal.pone.0166626
27. Chirivi RG, Garofalo A, Padura IM, Mantovani A, Giavazzi R. Interleukin 1
receptor antagonist inhibits the augmentation of metastasis induced by interleukin 1 or
lipopolysaccharide in a human melanoma/nude mouse system. Cancer Res (1993) 53
(20):5051–4.
9. Luo M, Wang F, Zhang H, To KKW, Wu S, Chen Z, et al. Mitomycin c enhanced
the efficacy of PD-L1 blockade in non-small cell lung cancer. Signal Transduct Target
Ther (2020) 5(1):141. doi: 10.1038/s41392-020-0200-4
28. Vidal-Vanaclocha F, Amezaga C, Asumendi A, Kaplanski G, Dinarello CA.
Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma
hepatic metastases. Cancer Res (1994) 54(10):2667–72.
10. Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell
transcriptomic data across different conditions, technologies, and species. Nat
Biotechnol (2018) 36(5):411–20. doi: 10.1038/nbt.4096
29. Zhuang Z, Ju HQ, Aguilar M, Gocho T, Li H, Iida T, et al. IL1 receptor
antagonist inhibits pancreatic cancer growth by abrogating NF-kB activation. Clin
Cancer Res (2016) 22(6):1432–44. doi: 10.1158/1078-0432.CCR-14-3382
11. Kim N, Kim HK, Lee K, Hong Y, Cho JH, Choi JW, et al. Single-cell RNA
sequencing demonstrates the molecular and cellular reprogramming of metastatic lung
adenocarcinoma. Nat Commun (2020) 11(1):2285. doi: 10.1038/s41467-020-16164-1
30. Lust JA, Lacy MQ, Zeldenrust SR, Witzig TE, Moon-Tasson LL, Dinarello CA,
et al. Reduction in c-reactive protein indicates successful targeting of the IL-1/IL-6 axis
resulting in improved survival in early stage multiple myeloma. Am J Hematol (2016)
91(6):571–4. doi: 10.1002/ajh.24352
12. He D, Wang D, Lu P, Yang N, Xue Z, Zhu X, et al. Single-cell RNA sequencing
reveals heterogeneous tumor and immune cell populations in early-stage lung
adenocarcinomas harboring EGFR mutations. Oncogene (2021) 40(2):355–68.
doi: 10.1038/s41388-020-01528-0
31. Wu TC, Xu K, Martinek J, Young RR, Banchereau R, George J, et al. IL1 receptor
antagonist controls transcriptional signature of inflammation in patients with
metastatic breast cancer. Cancer Res (2018) 78(18):5243–58. doi: 10.1158/00085472.CAN-18-0413
32. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C,
et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J
Med (2017) 377(12):1119–31. doi: 10.1056/NEJMoa1707914
33. Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ, et al.
Effect of interleukin-1b inhibition with canakinumab on incident lung cancer in
patients with atherosclerosis: exploratory results from a randomised, double-blind,
placebo-controlled trial. Lancet (2017) 390(10105):1833–42. doi: 10.1016/S0140-6736
(17)32247-X
34. Garon EB, Chih-Hsin Yang J, Dubinett SM. The role of interleukin 1b in the
pathogenesis of lung cancer. JTO Clin Res Rep (2020) 1(1):100001. doi: 10.1016/
j.jtocrr.2020.100001
35. Paz-Ares LG, Garon EB, Ardizzoni A, Barlesi F, Castro BCC, Marchi PD, et al.
The CANOPY program: canakinumab in patients (pts) with non-small cell lung cancer
(NSCLC). J Clin On col (2019) 37(15(sup pl) :TP S9124. doi: 10.1200/
JCO.2019.37.15_suppl.TPS9124
36. Garrido P, Pujol J-L, Kim ES, Lee JM, Tsuboi M, Gó mez-Rueda A, et al.
Canakinumab with and without pembrolizumab in patients with resecfitable non-
13. Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, et al.
Therapy-induced evolution of human lung cancer revealed by single-cell RNA
sequencing. Cell (2020) 182(5):1232–51 e22. doi: 10.1016/j.cell.2020.07.017
14. Shibahara D, Tanaka K, Iwama E, Kubo N, Ota K, Azuma K, et al. Intrinsic and
extrinsic regulation of PD-L2 expression in oncogene-driven non-small cell lung
cancer. J Thorac Oncol (2018) 13(7):926–37. doi: 10.1016/j.jtho.2018.03.012
15. Zong Z, Zou J, Mao R, Ma C, Li N, Wang J, et al. M1 macrophages induce PD-L1
expression in hepatocellular carcinoma cells through IL-1b signaling. Front Immunol
(2019) 10:1643. doi: 10.3389/fimmu.2019.01643
16. Huang G, Wen Q, Zhao Y, Gao Q, Bai Y. NF-kB plays a key role in inducing
CD274 expression in human monocytes after lipopolysaccharide treatment. PloS One
(2013) 8(4):e61602. doi: 10.1371/journal.pone.0061602
17. Tanaka K, Martinez GJ, Yan X, Long W, Ichiyama K, Chi X, et al. Regulation of
pathogenic T helper 17 cell differentiation by steroid receptor coactivator-3. Cell Rep
(2018) 23(8):2318–29. doi: 10.1016/j.celrep.2018.04.088
18. Schober P, Boer C, Schwarte LA. Correlation coefficients: appropriate use and
interpretation. Anesth Analg (2018) 126(5):1763–8. doi: 10.1213/ANE.00000
00000002864
Frontiers in Immunology
13
frontiersin.org
Hirayama et al.
10.3389/fimmu.2023.1192861
small-cell lung cancer: CANOPY-n study design. Future Oncol (2021) 17(12):1459–72.
doi: 10.2217/fon-2020-1098
37. Lythgoe MP, Prasad V. Repositioning canakinumab for non-small cell lung
cancer-important lessons for drug repurposing in oncology. Br J Cancer (2022) 127
(5):785–7. doi: 10.1038/s41416-022-01893-5
38. Lee JM, Tsuboi M, Kim ES, Mok TS, Garrido P. Overcoming immunosuppression
and pro-tumor inflammation in lung cancer with combined IL-1b and PD-1 inhibition.
Future Oncol (2022) 18(27):3085–100. doi: 10.2217/fon-2021-1567
39. Pretre V, Papadopoulos D, Regard J, Pelletier M, Woo J. Interleukin-1 (IL-1) and the
inflammasome in cancer. Cytokine (2022) 153:155850. doi: 10.1016/j.cyto.2022.155850
43. Liu Q, Li A, Tian Y, Wu JD, Liu Y, Li T, et al. The CXCL8-CXCR1/2 pathways in
cancer. Cytokine Growth Factor Rev (2016) 31:61–71. doi: 10.1016/j.cytogfr.2016.08.002
40. Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated
macrophages as treatment targets in oncology. Nat Rev Clin Oncol (2017) 14(7):399–
416. doi: 10.1038/nrclinonc.2016.217
46. Sun D, Ding A. MyD88-mediated stabilization of interferon-g-induced cytokine
and chemokine mRNA. Nat Immunol (2006) 7(4):375–81. doi: 10.1038/ni1308
44. Luo M, Xia Y, Wang F, Zhang H, Su D, Su C, et al. PD0325901, an ERK
inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma.
Acta Pharm Sin B (2021) 11(10):3120–33. doi: 10.1016/j.apsb.2021.03.010
45. Negishi H, Fujita Y, Yanai H, Sakaguchi S, Ouyang X, Shinohara M, et al.
Evidence for licensing of IFN-g-induced IFN regulatory factor 1 transcription factor by
MyD88 in toll-like receptor-dependent gene induction program. Proc Natl Acad Sci
U.S.A. (2006) 103(41):15136–41. doi: 10.1073/pnas.0607181103
41. Yuen KC, Liu LF, Gupta V, Madireddi S, Keerthivasan S, Li C, et al. High
systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1
blockade. Nat Med (2020) 26(5):693–8. doi: 10.1038/s41591-020-0860-1
47. Yoneshima Y, Ijichi K, Anai S, Ota K, Otsubo K, Iwama E, et al. PD-L1
expression in lung adenocarcinoma harboring EGFR mutations or
ALK rearrangements. Lung Cancer (2018) 118:36–40. doi: 10.1016/j.lungcan.
2018.01.024
42. Fu XT, Dai Z, Song K, Zhang ZJ, Zhou ZJ, Zhou SL, et al. Macrophage-secreted IL-8
induces epithelial-mesenchymal transition in hepatocellular carcinoma cells by activating the
JAK2/STAT3/Snail pathway. Int J Oncol (2015) 46(2):587–96. doi: 10.3892/ijo.2014.2761
48. Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance,
and toxicity to immune checkpoint blockade. Cell (2021) 184(21):5309–37.
doi: 10.1016/j.cell.2021.09.020
Frontiers in Immunology
14
frontiersin.org
...
論文の公開元へ
